Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1025 - 1032 of 12007 results
TikToker Drug Ads Spark Demands for FDA to Clarify Its Authority
February 16, 2024| News
Quality System Harmonization Is Here, But with Small Benefit to Device Industry
February 15, 2024| Blog| Viewpoint
Major Win for California Privacy Protection Agency: Enforcement of Regulations Can Begin Immediately
February 15, 2024| Blog| Viewpoint
USCIS Fee Increases May Have Unintended Consequences
February 15, 2024| News
Hiring Across the 49th Parallel: Traps for the Unwary for Cross-Border US-Canada Hires
February 14, 2024| Blog| Viewpoint
USCIS Online Organizational Accounts and Electronic Filing – the Future has Finally Arrived – Session 1
February 14, 2024| Webinar| Viewpoint
US Judges Are Warning Implementers To Take FRAND Negotiations Seriously, Or Else
February 14, 2024| News
Bitcoin ETF Approval Doesn't Mean SEC Approves Of Crypto
February 13, 2024| News
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|